Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 2
Submit an article Journal homepage
175
Views
1
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants

Junichi Yamamotoa UCB Pharma, Tokyo, Japan
,
Kaori Ikedaa UCB Pharma, Tokyo, Japan
&
Armel Stockisb Quantitative Clinical Pharmacology Department, UCB Pharma, Brussels, BelgiumCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0815-5264
ORCID Icon
Pages 146-151 | Received 08 Jan 2022, Accepted 14 Mar 2022, Published online: 28 Mar 2022

References

  • Beghi E. 2016. Addressing the burden of epilepsy: many unmet needs. Pharmacol Res. 107:79–84.
  • Ben-Menachem E, Mameniškienė R, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, Whitesides J, McDonough B, Eckhardt K, 2016. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 87(3):314–323.
  • Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S, 2014. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 55(1):57–66.
  • Fisher R, Emde Boas WV, Blume W, Elger C, Genton P, Lee P, Engel J, 2005. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 46(4):470–472.
  • French J, 1994. The long-term therapeutic management of epilepsy. Ann Intern Med. 120(5):411–422.
  • Klein P, Biton V, Dilley D, Barnes M, Schiemann J, Lu Z, 2016. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia. 57(7):1130–1138.
  • Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P, 2015. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 56(12):1890–1898.
  • Klitgaard H, Matagne A, Nicolas J-M, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, et al. 2016. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 57(4):538–548.
  • Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H, 2008. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 154(8):1662–1671.
  • Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S, 2014. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 55(1):47–56.
  • Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, Stockis A, 2007. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 63(6):680–688.
  • Schoemaker R, Wade JE, Stockis A, 2016. Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol. 56(12):1591–1602.
  • Schoemaker R, Wade JR, D'Souza J, Stockis A, 2017. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures. Epilepsy Res. 137:95–100.
  • Stockis A, Hartstra J, Mollet M, Hadi S, 2016. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 57(8):1288–1293.
  • Stockis A, Watanabe S, Rouits E, Matsuguma K, Irie S, 2014. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab Pharmacokinet. 29(5):394–399.
  • UCB Inc. 2021. Briviact® US prescribing information. https://www.briviact.com/briviact-PI.pdf.
  • UCB Pharma. 2020. Briviact® summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf.
  • Williams EJ, 1949. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Chem. 2(2):149–168.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.